Day: September 3, 2025

HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following September investor conferences:H.C. Wainwright 27th Annual Global Investment ConferenceDate: Tuesday, September 9, 2025Format: 1×1 Investor Meetings Only   Morgan Stanley 23rd Annual Global Healthcare Conference Date: Wednesday, September 10, 2025Format: Fireside Chat Time: 2:35 PM – 3:10 PM EST and 1×1 Investor Meetings   About vTv TherapeuticsvTv Therapeutics is a late-stage biopharmaceutical company focused on developing...

MONTEVIDEO, Uruguay, Sept. 03, 2025 (GLOBE NEWSWIRE) — DLocal Limited (“dLocal” or the “Company”), (NASDAQ:DLO) a technology-first payments platform, today announced the commencement of an underwritten registered secondary offering of 15,000,000 Class A common shares by an entity associated with General Atlantic (the “Selling Shareholder”). The Company is not selling any Class A common shares in the offering and will not receive any proceeds from the offering. In connection with the offering, the Selling Shareholder expects to grant the underwriters a 30-day option to purchase up to an additional 2,250,000 Class A common shares at the public offering price, less underwriting discounts and commissions. The offering is being made through an underwriting group led by J.P. Morgan, Goldman Sachs & Co. LLC and Morgan Stanley, who...

DALLAS, Sept. 03, 2025 (GLOBE NEWSWIRE) — P10, Inc. (NYSE: PX), a leading private markets solutions provider, today announced that Chairman and Chief Executive Officer, Luke Sarsfield, and EVP and Chief Administrative Officer, Mark Hood, will participate in a fireside chat at the Barclays 23rd Annual Global Financial Services Conference on Monday, September 8, 2025, scheduled for 12:00 P.M. Eastern Time. A webcast of the discussion will be available on the Investor Relations section of P10’s website at ir.p10alts.com/events. For those unable to listen to the live webcast, a replay will be available on the Events page of P10’s website by the end of the same day. About P10P10 (NYSE: PX) is a leading private markets solutions provider with over $40 billion in assets under management as of June 30, 2025. P10 invests across Private...

SOLANA BEACH, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced it has commenced an underwritten public offering of its common stock and/or pre-funded warrants. All shares of common stock and/or pre-funded warrants in the offering are to be offered by the Company. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. R.F. Lafferty & Co., Inc. is acting as the sole book-running manager for the offering. The shares of common stock and/or pre-funded warrants are being offered...

Châtillon, France, September 3, 2025 DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025, at 11:30am ET, in New York, NY. A live webcast of the fireside chat can be accessed here, and will also be available on the Events section of the Company’s Investors website: https://dbv-technologies.com/investor-overview/events/, with an archived replay accessible for 90 days following the event. About DBV TechnologiesDBV Technologies is a clinical-stage biopharmaceutical company...

Hong Kong, Sept. 03, 2025 (GLOBE NEWSWIRE) — BUUU Group Limited (Nasdaq: BUUU) (the “Company”), an established  meetings, incentives, conferences and exhibitions (“MICE”) solutions provider based in Hong Kong , today announced the partial exercise of the over-allotment option (the “Over-Allotment”) by the underwriter (the “Underwriter”) of its initial public offering (the “Offering”) to purchase an additional 175,000 Class A ordinary shares (the “Class A Ordinary Shares”) of the Company at the public offering price of US$4.00 per share and the closing of such issuance. The Class A Ordinary Shares commenced trading on the Nasdaq Capital Market on August 14, 2025, under the symbol “BUUU.” The Company received aggregate gross proceeds of US$700,000 from this Over-Allotment closing, and the aggregate gross proceeds from the Offering...

Results published in the Journal of Clinical Psychopharmacology SALT LAKE CITY, Sept. 03, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced the publication of a new meta-analysis of six prospective controlled studies1 that included 3,532 adults with major depressive disorder (MDD). The meta-analysis showed that when GeneSight® Psychotropic test results were available to treating clinicians, there were significant improvements in response and remission rates for patients with MDD, compared to treatment as usual (TAU). Specifically, compared to TAU, patients in the GeneSight arm were:41% more likely to achieve remission. 30% more likely to achieve response.“This meta-analysis summarizes the clinical evidence of the GeneSight test, demonstrating...

ATLANTA, GA., Sept. 03, 2025 (GLOBE NEWSWIRE) — Americold Realty Trust (NYSE: COLD), a global leader in temperature-controlled logistics, real estate, and value-added services focused on the ownership, operation, acquisition and development of temperature-controlled warehouses, today announced that its Board of Directors has declared a dividend of $0.23 per share for the third quarter of 2025, payable to holders of the Company’s common stock. This is consistent with the dividend for the second quarter of 2025 and reflects an increase of 5% from the prior year. The dividend will be payable in cash on October 15, 2025 to stockholders of record at the close of business on September 30, 2025. About Americold Realty Trust, Inc. Americold (NYSE: COLD) is a global leader in temperature-controlled logistics and real estate, with a more...

DURHAM, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) —  374Water Inc. (NASDAQ: SCWO) (“374Water” or the “Company”), a global leader in organic waste destruction technology and services for the municipal, federal, and industrial markets, today announced recent open-market stock purchases by Company insiders, including Board members and senior management. 374Water President and CEO Chris Gannon, said, “These share purchases underscore our confidence in 374Water’s vision and the tremendous opportunities ahead for our AirSCWO (“AS”) technology. We believe there is a significant disconnect between our current price and the value we can deliver in the coming years. We have made considerable progress and expect continued advances for our AS technology with ongoing system deployments. With the completion of numerous municipal, federal,...